Posts tagged Arbutus
Arbutus licensee Alnylam posts positive Phase 3 results

Arbutus Biopharma’s (NASDAQ:ABUS) lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals (NASDAQ:ALNY), announced that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint and all secondary endpoints.

Read More
Arbutus, Spring Bank in HBV collaboration

Arbutus Biopharma (NASDAQ:ABUS) and Spring Bank Pharmaceuticals (NASDAQ:SBPH) agreed to perform collaborative preclinical studies in chronic Hepatitis B virus (HBV).

Read More
WB starts 4 chronic Hep B biotechs at outperform

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier.

“Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each in cumulative global sales over a span of two decades,” writes analyst Katherine Xu.

Read More